Gilead Sciences reports strong Q2 2025 results, driven by robust HIV drug sales, and raises full-year guidance, making it a top performer in the S&P 500 and Nasdaq 100.
Manchester United unveils a £50 million redevelopment of its Carrington Training Complex, aiming to restore the club's competitive edge with state-of-the-art facilities and a focus on player wellbeing.
Gilead Sciences reports strong Q2 2025 results, driven by robust HIV drug sales, and raises full-year guidance, making it a top performer in the S&P 500 and Nasdaq 100.
Manchester United unveils a £50 million redevelopment of its Carrington Training Complex, aiming to restore the club's competitive edge with state-of-the-art facilities and a focus on player wellbeing.